ARDS   $0.29  -6.77% Market Open

Aridis Pharmaceuticals Inc
Last Events:

2023-07-19 Trend pattern changed from расходящийся клин с наклоном вверх to восходящий треугольник.

2023-07-19 Signal in Stochastic changed from bearish reversal to bearish. The stochastic indicator is in the lower part of the neutral territory and it falls. These factors indicate that negative dynamics persists. Last signal: down-crossing the middle level.

2023-07-19 Signal in MACD changed from bullish to bullish weakening. Oscillator MACD is in the positive territory it's higher than the signal line and falls. These factors mean that the growing trend persists, but the growth rate is declining. Last signal: signal line crossed the middle level.

2023-07-19 Signal in RSI changed from bearish reversal to bearish. RSI indicator is in the lower part of the neutral territory and it falls. These factors indicate that negative dynamics persists. Last signal: exit from the overbought zone.

2023-07-19 Signal in EMA50 changed from bullish reversal to bearish reversal. The price is trying to cross down the moving average line If the intersection will be successful, then a downside trend can be formed.

2023-07-19 Signal in EMA20 changed from bullish reversal to bearish reversal. The price is trying to cross down the moving average line If the intersection will be successful, then a downside trend can be formed.

2023-07-18 Trend pattern changed from нисходящий клин to расходящийся клин с наклоном вверх.

2023-07-18 Signal in Stochastic changed from bearish to bearish reversal. The stochastic indicator is in the upper part of the neutral territory and it falls. These factors indicate that the downside trend is confirmed. Last signal: exit from the overbought zone.


Current temperature: 1.84
ST: 0, Cor:

50-50 Year Forecast
Low with 49% probability: 0.22
Target: 10.00
High with 49% probability: 1.48
Analyst Recommendations:
Number of estimates 1
Target Price Mean 10.00
Mean unverified/preliminary 10.00 / 10.00
Target Price Low / High 10.00 / 10.00
Median / STD DEV 10.00 / 0.00
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Sell - Sell
rsi Sell Sell Sell
macd - Sell -
stoch Sell - -
ma20 Buy ActivelyBuy -
ma50 Sell - -
ma100 Sell - -
Candlestick PatternJuly 5, 2023 Doji - is formed when the open and the close are the same or very close. The body of candle is small. The length of the shadows are not important. The appearance of a Doji should alert the investor of major indecision.
ISIN US0403341045
ceo Dr. Vu L. Truong Ph.D.
Website https://www.aridispharma.com
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia. The company is also developing AR-320, a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR 501, an inhaled gallium citrate, which is in Phase 1/2a for the treatment of chronic lung infection associated with cystic fibrosis; and AR-101, a human IgM mAb, which is in Phase II clinical trials targeting Pseudomonas aeruginosa liposaccharides serotype O11. In addition, it develops AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-701, a cocktail of two fully human immunoglobulin 1. The company was founded in 2003 and is headquartered in Los Gatos, California.